Drug Combination Details
| General Information of the Combination (ID: C92070) | |||||
|---|---|---|---|---|---|
| Name | Semaglutide NP Info | + | Rosiglitazone Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Diabetic retinopathy
[ICD-11: 9B71]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | IL1B | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Increase | ROS accumulation | ||||
| In-vivo Model | Fifty healthy male Sprague-Dawley (SD) rats with eight-week-old and body weight of 200.0 +/- 18.4 g were used in this study. | |||||
| Experimental
Result(s) |
Combined semaglutide with RSG exhibited synergistically protective efficacies on retinal cells by decreasing the GFAP expression, inhibiting oxidative stress and PI3K/Akt/MTOR signaling-transduction in DR model rats. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combination therapy with semaglutide and rosiglitazone as a synergistic treatment for diabetic retinopathy in rodent animals. Life Sci. 2021 Mar 15;269:119013. | |||
